Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug Ozempic.) Eli Lilly is hot on Novo Nordisk's heels with its new obesity drug Zepbound. Pfizer…#novonordisk #elililly #pfe #lilly #pf07976016 #danuglipron #pfizer #nash #vikingtherapeutics #seagen (Source: Reuters: Health)
Source: Reuters: Health - March 15, 2024 Category: Consumer Health News Source Type: news

' Making the Invisible Visible': CGMs Offer Insights for T2D'Making the Invisible Visible': CGMs Offer Insights for T2D
Results from several studies of continuous glucose monitoring for people with type 2 diabetes found improved clinical parameters even among those who don ' t use insulin.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 14, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

Slowing of Peripheral Artery Disease: Another Liraglutide Benefit?
(MedPage Today) -- Liraglutide (Victoza), a type 2 diabetes drug, may help prevent peripheral artery disease (PAD) progression, the small, open-label STARDUST trial suggested. Over 6 months, adults with type 2 diabetes on subcutaneous liraglutide... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 14, 2024 Category: Cardiology Source Type: news

Disease Knowledge Limited Among Individuals With Type 2 Diabetes
WEDNESDAY, March 13, 2024 -- There is considerable room for improvement of disease knowledge among individuals with type 2 diabetes (T2D), according to a study published online March 7 in Frontiers in Public Health.Pedro L. Ferreira, Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2024 Category: Pharmaceuticals Source Type: news

Amid Global GLP-1 Shortages, Doctors Prioritize Patients Amid Global GLP-1 Shortages, Doctors Prioritize Patients
Some governments are asking clinicians to reserve prescriptions for those with type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 13, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

Former CFO sues Peninsula drug company, alleges domestic violence incident led to her firing
Structure is in the hot area of GLP-1 drugs, hoping to make easier-to-take oral drugs against Type 2 diabetes and obesity. Ding joined as CFO in 2021 as the company eyed an IPO. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 13, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

The Role of Growth Hormone Mediators in Youth-Onset T2D The Role of Growth Hormone Mediators in Youth-Onset T2D
The loss of glycemic control in youth-onset type 2 diabetes (T2D) is associated with changes in growth hormone mediators, a new study found.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 12, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

The banyan tree of health: Combating the titan twindemic of diabetes and obesity
The twindemic of type 2 diabetes and obesity is a major challenge in India, with over 100 million adults living with diabetes and roughly 250 million adults being overweight or obese. (Source: The Economic Times)
Source: The Economic Times - March 11, 2024 Category: Consumer Health News Source Type: news

Is a 1-Hour Glucose Test Better at Predicting T2D Risk? Is a 1-Hour Glucose Test Better at Predicting T2D Risk?
A new International Diabetes Federation position statement calls for improved prediction of type 2 diabetes in high-risk individuals using a 1-hour glucose tolerance test.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 11, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news

Wegovy Is Good for More Than Just Weight Loss
The obesity drug Wegovy can now claim to lower the risk of heart attack, stroke, and other cardiovascular issues in people who are overweight or who have obesity, and also have cardiovascular disease. It’s the first weight-loss drug to carry an indication for heart benefits. The U.S. Food and Drug Administration (FDA) approved the addition to the label on March 8 based on a study from Wegovy’s manufacturer, Novo Nordisk, showing that the drug lowered the risk of heart attack, stroke, or dying of heart-related issues in this population by 20% compared to people receiving placebo. [time-brightcove not-tgx=...
Source: TIME: Health - March 8, 2024 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news

Roche presents positive topline CGM accuracy data at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
At the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, Roche shared recent accuracy data for its new Accu-Chek SmartGuide solution for real-time continuous glucose monitoring (rtCGM)International experts discussed how a novel CGM solution using prediction capabilities can address unmet needs of people with diabetes at the Roche symposiumThe presented study results underlined the accurate and safe performance of the solutionBasel, 7 March, 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented the latest data on its novel solution for continuous glucose monitoring. ...
Source: Roche Investor Update - March 7, 2024 Category: Pharmaceuticals Source Type: news

Short Sleep Duration Linked to Increased Risk for Developing T2D
THURSDAY, March 7, 2024 -- Habitual short sleep duration is associated with an increased risk for developing type 2 diabetes (T2D), according to a study published online March 5 in JAMA Network Open. Diana Aline Nôga, Ph.D., from Uppsala... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news

Short Sleep Ups Type 2 Diabetes Risk, Even With Healthy Diet Short Sleep Ups Type 2 Diabetes Risk, Even With Healthy Diet
Getting fewer than 6 hours of sleep a night increased the risk compared with 8 hours or more, and eating less red meat and more fish, fruits, and vegetables did not change that.Medscape News UK (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 6, 2024 Category: Endocrinology Tags: Internal Medicine Source Type: news

Real-World Data Show Abbott's FreeStyle Libre ® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes
(Source: Abbott.com)
Source: Abbott.com - March 6, 2024 Category: Pharmaceuticals Source Type: news

FDA Clears First OTC Continuous Blood Glucose Monitor
WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration on Tuesday approved the country ' s first continuous glucose monitor for type 2 diabetes. The new Dexcom Stelo Glucose Biosensor System, which will be available by summer, is intended... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 6, 2024 Category: General Medicine Source Type: news